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February 2016 Abstracts S47are highly magnetic, and stable in serum solutions for
extended periods of time. The MNPs are incubated with
cells in 1X PBS for 3h for receptor binding at 37C after
which particles bound to cells are magnetically separated
with a pull force of 57 lbs. Cells are then washed and
counted using an automated algorithm. Thewhole process
has been optimized to a minimum cell population of 100
and can be theoretically reduced to a 2h process which
makes this extremely effective for clinical evaluations and
straightforward. Similar protocol was used when the cells
were spiked in blood plasma and captured. Our data
suggests strong correlation between number of A549 cell
captured when Herceptin conjugated MNPs are used
(96%difference vs HCC827), while Cetuximab conjugated
MNPs pull both HCC827 aswell as A549 (31%difference).
We expect to reduce the cell capture limit to less than 10
cells in further experiments as required for patient testing.
In conclusion, our results show that MNP based sensing
allows both cell marker characterization as well as cap-
ture simultaneously. The nanocubes allow better charac-
terization of HER2 and EGFR positive metastatic
cell subpopulations and provide easier prediction of tu-
mor heterogeneity without resorting to invasive proce-
dures.
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NSCLC is diagnosed in an estimated 220,000 patients
each year with ﬁve-year overall survival rates of 16
percent. A recent report conﬁrmed that 16 percent of
NSCLC patients carry oncogenic KRAS mutation. Patients
with KRAS mutation often harbored in wild-type EGFR
tumors, are resistant to Tyrosine Kinase Inhibitors (TKI).
A potent drug targeted against KRAS mutation has not
yet been developed and the objective response rate with
the current standard of care is a meager three percent.
Interestingly, KRAS knockdown using siRNA sensitizes
tumor to TKI with a good response rate. Retroviral
vectors, liposomes, polymeric particles and metallic
nanoparticles have been used as carriers to deliver
siRNA within cancer-site. However, protecting siRNA
from serum degradation and cytoplasmic delivery are
two major issues. Also, in most cases, a mere siRNA
mediated oncogene knockdown does not have signiﬁcantimpact on the cancer cell apoptosis since the cells adapt
to another effector survival pathway. To overcome these
challenges and understand the adopted effector down-
stream mechanism post oncogene knockdown, we hier-
archically created a well-deﬁned 200nm tri-block
nanocomplex with each sublayer contributing to a deﬁ-
nite function. The nanocomplex comprises of an enzy-
matically cleavable protein (gelatin) nanoparticle
encapsulated with a TKI (geﬁtinib) and surface func-
tionalized with an antibody (Cetuximab)-siRNA (Kras
G12C) conjugate. Detailed characterization revealed each
nanoparticle of the tri-block nanocomplex comprised of
w400 antibodies andw800 siRNA. We protected 14KDa
siRNA within 150KDa cetuximab and sandwiched it be-
tween antibody and gelatin nanoparticle to protect from
serum degradation, conﬁrmed using SDS-PAGE. To
investigate cellular activity, we incubated the nano-
complex in drug resistant Kras G12C mutant NSCLC
(H23 cells). The nanocomplex, when delivered to cyto-
plasm of the drug resistant H23 cells for oncogene
knockdown, sensitized the affected cells to the co-
delivered TKI. Knockdown of the oncogene was
conﬁrmed by monitoring the PI3K and MAPK down-
stream protein expression levels. Western blot results
indicated abrogation of activated PI3K and MAPK
pathway proteins. In vitro assays revealed 95% toxicity
for the nanocomplex containing 5mM geﬁtinib as against
0-10% toxicity for 5mM stand-alone geﬁtinib. rtPCR
showed downregulation of DUSP6, a known effect for
H23 cells with knocked down oncogene. Flow cytometry
results showed 2 fold higher internalization of the
nanocomplex compared to transfected siRNA. However,
in the absence of TKI, the nanocomplex showed no
toxicity suggesting the cells adapt to a parallel effector
pathway for survival, although phosphorylated Mek, Erk
and Akt were downregulated leading us to investigate a
possible survival mechanism. We hypothesized that the
downstream signaling is governed by Gab1 assisted
pathway. In H23 cells, activated ERK results in phos-
phorylation of Gab1 on serine and threonine residues
and forms Gab1-p85 PI3K complex that are adjacent to
p85 PI3K binding sites. Knocking down the oncogene
dephosphorylated Erk, and negated the complex forma-
tion. This further cascaded in tyrosine phosphorylation
at Tyr627 domain of Gab1, which is known to associate
with downstream of EGFR but upstream of Ras, to
regulate EGFR signaling through several positive feed-
back loops. We found that TKI binds to this speciﬁc
phosphotyrosine domain of Gab1, the domain that is
responsible for Gab1-Egfr association. In the absence of a
TKI, the feedback loop mediated via Gab1 provides a
route for survival but is sensitized by abrogation of
Gab1-Egfr complex formation post oncogene knockdown
when exposed to a TKI. The outcome of this study
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Accumulating evidence indicates that altered miRNA
expression is crucially involved in lung cancer develop-
ment, though scant information is available regarding how
MYC, an archetypical oncogene, is regulated by miRNAs,
especially via a mechanism involving MYC cofactors.
Although various oncogenes have thus far been identiﬁed
to be altered in various types of lung cancer, MYC is among
the most frequently ampliﬁed and overexpressed. The
MYC gene encodes a transcription factor that regulates a
wide variety of genes involved in control of cell growth,
proliferation, and apoptotic cell death. The transcriptional
activity of MYC is tightly controlled for proper transcrip-
tional regulation through various mechanisms, which
include MYC expression itself at both transcriptional and
posttranscriptional levels, as well as its interaction with
cofactors that functionally cooperate with MYC. Unfortu-
nately, very little is known thus far about how MYC is
regulated by miRNAs in lung cancer cells, especially via
the latter mechanism involving MYC cofactors.
In this study, we attempted to identify miRNAs
involved in regulation of MYC transcriptional activity in
lung cancer. To this end, we utilized an integrative
approach with combinatorial usage of miRNA and mRNA
expression proﬁle datasets of patient tumor tissues, as
well as those of MYC-inducible cell lines in vitro. Our re-
sults allowed us to identify multiple miRNAs reported as
either directly downstream or upstream of MYC, sup-
porting the robustness of our strategy. The former ex-
amples included the miR-17-92 cluster, miR-22, miR-26a,
miR-30a-3p, and miR-30e-3p, all of which were previ-
ously shown to be under MYC-mediated transcriptionalregulation, while the latter instances were comprised of
let-7, miR-34a and miR-24, which have been reported to
directly repress MYC expression via binding to a target
site at the 3’UTR of MYC. Intriguingly, our integrative
approach also led us to identify miR-342-3p, which we
found to be amiRNA indirectly regulatingMYC activity via
direct inhibition of E2F1, a MYC-cooperating transcrip-
tion factor. Furthermore, miR-342-3p module activity,
which we deﬁned as a gene set reﬂecting the experi-
mentally substantiated inﬂuence ofmiR-342-3p onmRNA
expression, was found to be inversely correlated with
MYC activity reﬂected by MYC module activity in 3 inde-
pendent datasets of lung adenocarcinoma patients. Our
present ﬁndings also clearly demonstrate that miR-342-
3p plays important roles to inhibit cell cycle progression
and proliferation in lung adenocarcinoma cell lines.
Taken together, our integrative approach appears to
be useful to elucidate inter-regulatory relationships be-
tween miRNAs and protein coding genes of interest, even
those present in patient tumor tissues, which remains a
challenge to better understand the pathogenesis of this
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Immunoproteasome are a specialized form of multi-
subunit complexes called proteasome that degrade
intracellular proteins through the ubiquitin-proteasome
pathway. It can generate peptides with high speciﬁcity
for binding onto MHC class I molecules, hence a
suitable candidate for CD8þ T cell mediated cytotoxic
responses. The expression of the immunoproteasome
and its impact on antigen presentation in tumors of
epithelial origin is not well established. We have
investigated the constitutive and induced expression
patterns of immunoproteasome subunits in non-small
cell lung cancer (NSCLC) and their consequence on
antigen presentation. We also assessed the impact of
immunoproteasome expression on survival in early
stage NSCLC.
